A long way from
clinical results?
Making the Science
Shine
A stem cell company was years away from clinical trials. We focused on their peer reviewed publications to garner coverage of both the science and spread the attention from their CSO only to the researchers at prestigious universities co-publishing with him.
Results:
The company’s science was highlighted and picked up by publications worldwide, years ahead of clinical trials and commercialization. The company’s science became known and prestigious in a time period when it had no corporate news or milestones.
How We Did it:
We interviewed our
CSO and the other lead university scientist to extract from each the gist of
the study, the “take home,” and what it could mean in humans. In our press
release, we featured the outside scientist, along with ours to give the results
a broader endorsement. Working under embargo with the peer review publication,
we shopped the story around to top medical and science reporters in the
business/financial news.
We got featured coverage by Reuters’ 
Maggie Fox, one of the nation’s most
prestigious medical and science writers. The story also ran in Scientific
American.
We also got
coverage of the research in Bloomberg 
, with the leading reporter covering stem
cells for the outlet. This set us up well for continued coverage in this outlet
picked up in newspapers and on websites internationally.
A second
peer-reviewed publication on a different topic was written up by UPI
, resulting
in newspaper coverage worldwide once more.